Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects has been an essential resource for scientists and clinicians in this field since its original publication in 2015. The third edition of this work has been completely updated and expanded with the latest scientific and clinical developments in Systemic Lupus Erythematosus (SLE) to date. Contributors at the forefront of each topic come together to enhance content on epidemiology and diagnosis, pathogenesis, mechanisms of tissue damage, clinical aspects of the disease, antiphospholipid syndrome, and treatments. Also added is the latest information on new treatments, criteria, monogenic forms of lupus, insights on the role of microbiome, and advances in understanding disease pathogenesis. This must-have reference is an indispensable resource for specialists in the diagnosis and management of patients with SLE as well as early career or experienced investigators studying basic aspects of the disease. It is a tool for measurement of clinical activity for pharmaceutical development and basic research of the disease, and a key reference work for hospital libraries.
1. Introduction - p. xxxi 2. Part I. Epidemiology and diagnosis - p. P1 3. Chapter 1. Transcendental intuitive dogmas and ignorance of causality hinder advanced insight into SLE—Historical and current contexts - p. 3 4. Chapter 2. The patient - p. 21 5. Chapter 3. Practicing law with lupus: Navigating the dual identity of patient and practitioner - p. 31 6. Chapter 4. Epidemiology - p. 33 7. Chapter 5. Measuring disease activity - p. 45 8. Chapter 6. Disease development and outcome - p. 67 9. Chapter 7. Socioeconomic aspects of SLE - p. 81 10. Chapter 8. Biomarkers in lupus nephritis - p. 97 11. Part II. Pathogenesis - p. P2 12. Chapter 9. Overview of the pathogenesis of systemic lupus erythematosus - p. 109 13. Chapter 10. Systemic lupus erythematosus and the environment - p. 119 14. Chapter 11. Genes and genetics in human SLE - p. 135 15. Chapter 12. Monogenic lupus - p. 161 16. Chapter 13. Hormones in systemic lupus erythematosus - p. 177 17. Chapter 14. Clinical aspects of the complement system in systemic lupus erythematosus - p. 205 18. Chapter 15. T cells - p. 221 19. Chapter 16. B cells in SLE - p. 231 20. Chapter 17. Neutrophils in systemic lupus erythematosus - p. 245 21. Chapter 18. Role of dendritic cell in systemic lupus erythematosus pathophysiology - p. 257 22. Chapter 19. Role of platelets in systemic lupus erythematosus - p. 273 23. Chapter 20. Cytokines in systemic lupus erythematosus - p. 283 24. Chapter 21. RNA/DNA sensing in SLE - p. 293 25. Chapter 22. The role of interferons in systemic lupus erythematosus - p. 309 26. Chapter 23. Humoral pathogenesis: Fcγ receptors in autoimmunity and end-organ damage - p. 325 27. Chapter 24. Cell death in SLE - p. 349 28. Chapter 25. Infections in early systemic lupus erythematosus pathogenesis - p. 359 29. Chapter 26. Microbiota influences on systemic lupus erythematosus and Sjögren's syndrome - p. 369 30. Chapter 27. Origin of autoantibodies - p. 389 31. Chapter 28. Anti-DNA antibodies - p. 399 32. Chapter 29. Anti-histone and anti-spliceosome antibodies - p. 409 33. Chapter 30. Immune complexes in systemic lupus erythematosus - p. 423 34. Chapter 31. Noncoding RNAs in systemic lupus erythematosus - p. 433 35. Chapter 32. Immunometabolism of systemic lupus erythematosus - p. 445 36. Chapter 33. Epigenetics - p. 461 37. Chapter 34. Modeling lupus in mice - p. 481 38. Part III. Mechanisms of tissue damage - p. P3 39. Chapter 35. Pathogenesis of lupus nephitis - p. 499 40. Chapter 36. Mechanisms of vascular damage in systemic lupus erythematosus - p. 517 41. Chapter 37. Mechanisms involved in skin injury - p. 529 42. Chapter 38. Pathogenesis of tissue injury in the brain in patients with systemic lupus erythematosus - p. 541 43. Part IV. Clinical aspects of the disease - p. P4 44. Chapter 39. Constitutional symptoms and fatigue in systemic lupus erythematosus - p. 551 45. Chapter 40. The musculoskeletal system in SLE - p. 565 46. Chapter 41. Cutaneous lupus erythematosus - p. 579 47. Chapter 42. The clinical evaluation of kidney disease in systemic lupus erythematosus - p. 591 48. Chapter 43. The pathology of lupus nephritis - p. 605 49. Chapter 44. Cardiovascular disease in systemic lupus erythematosus: An update - p. 633 50. Chapter 45. The lung in systemic lupus erythematosus - p. 649 51. Chapter 46. Vasculitis in SLE - p. 663 52. Chapter 47. Gastrointestinal, hepatic, and pancreatic disorders in systemic lupus erythematosus - p. 667 53. Chapter 48. Infections in patients with systemic lupus erythematosus - p. 683 54. Chapter 49. Malignancies in systemic lupus erythematosus - p. 701 55. Chapter 50. The nervous system in systemic lupus erythematosus - p. 717 56. Chapter 51. Psychiatric lupus - p. 731 57. Chapter 52. Overlap syndromes - p. 747 58. Chapter 53. Systemic lupus erythematosus and the eye - p. 755 59. Chapter 54. Fertility and pregnancy in systemic lupus erythematosus - p. 771 60. Chapter 55. Neonatal lupus: Clinical spectrum, biomarkers, pathogenesis, and approach to treatment - p. 781 61. Chapter 56. Incomplete lupus syndromes - p. 799 62. Chapter 57. Lupus in children and adolescents - p. 807 63. Chapter 58. Drug-induced lupus - p. 817 64. Chapter 59. Accrual of organ damage in lupus - p. 831 65. Part V. Antiphospholipid syndrome - p. P5 66. Chapter 60. Pathogenesis of antiphospholipid syndrome - p. 841 67. Chapter 61. Antibodies and diagnostic tests in antiphosholipid syndrome - p. 853 68. Chapter 62. Clinical manifestations - p. 867 69. Part VI. Treatment of the disease - p. P6 70. Chapter 63. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus - p. 877 71. Chapter 64. The antimalarials in the treatment of lupus - p. 885 72. Chapter 65. Systemic glucocorticoids - p. 895 73. Chapter 66. Cytotoxic drug treatment - p. 911 74. Chapter 67. Treatment of antiphospholipid syndrome - p. 925 75. Chapter 68. New treatments for systemic lupus erythematosus - p. 933 76. Chapter 69. Cellular therapies for lupus - p. 947 77. Index - p. 959
Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects has been an essential resource for scientists and clinicians in this field since its original publication in 2015. The third edition of this work has been completely updated and expanded with the latest scientific and clinical developments in Systemic Lupus Erythematosus (SLE) to date. Contributors at the forefront of each topic come together to enhance content on epidemiology and diagnosis, pathogenesis, mechanisms of tissue damage, clinical aspects of the disease, antiphospholipid syndrome, and treatments. Also added is the latest information on new treatments, criteria, monogenic forms of lupus, insights on the role of microbiome, and advances in understanding disease pathogenesis. This must-have reference is an indispensable resource for specialists in the diagnosis and management of patients with SLE as well as early career or experienced investigators studying basic aspects of the disease. It is a tool for measurement of clinical activity for pharmaceutical development and basic research of the disease, and a key reference work for hospital libraries.
1. Introduction - p. xxxi 2. Part I. Epidemiology and diagnosis - p. P1 3. Chapter 1. Transcendental intuitive dogmas and ignorance of causality hinder advanced insight into SLE—Historical and current contexts - p. 3 4. Chapter 2. The patient - p. 21 5. Chapter 3. Practicing law with lupus: Navigating the dual identity of patient and practitioner - p. 31 6. Chapter 4. Epidemiology - p. 33 7. Chapter 5. Measuring disease activity - p. 45 8. Chapter 6. Disease development and outcome - p. 67 9. Chapter 7. Socioeconomic aspects of SLE - p. 81 10. Chapter 8. Biomarkers in lupus nephritis - p. 97 11. Part II. Pathogenesis - p. P2 12. Chapter 9. Overview of the pathogenesis of systemic lupus erythematosus - p. 109 13. Chapter 10. Systemic lupus erythematosus and the environment - p. 119 14. Chapter 11. Genes and genetics in human SLE - p. 135 15. Chapter 12. Monogenic lupus - p. 161 16. Chapter 13. Hormones in systemic lupus erythematosus - p. 177 17. Chapter 14. Clinical aspects of the complement system in systemic lupus erythematosus - p. 205 18. Chapter 15. T cells - p. 221 19. Chapter 16. B cells in SLE - p. 231 20. Chapter 17. Neutrophils in systemic lupus erythematosus - p. 245 21. Chapter 18. Role of dendritic cell in systemic lupus erythematosus pathophysiology - p. 257 22. Chapter 19. Role of platelets in systemic lupus erythematosus - p. 273 23. Chapter 20. Cytokines in systemic lupus erythematosus - p. 283 24. Chapter 21. RNA/DNA sensing in SLE - p. 293 25. Chapter 22. The role of interferons in systemic lupus erythematosus - p. 309 26. Chapter 23. Humoral pathogenesis: Fcγ receptors in autoimmunity and end-organ damage - p. 325 27. Chapter 24. Cell death in SLE - p. 349 28. Chapter 25. Infections in early systemic lupus erythematosus pathogenesis - p. 359 29. Chapter 26. Microbiota influences on systemic lupus erythematosus and Sjögren's syndrome - p. 369 30. Chapter 27. Origin of autoantibodies - p. 389 31. Chapter 28. Anti-DNA antibodies - p. 399 32. Chapter 29. Anti-histone and anti-spliceosome antibodies - p. 409 33. Chapter 30. Immune complexes in systemic lupus erythematosus - p. 423 34. Chapter 31. Noncoding RNAs in systemic lupus erythematosus - p. 433 35. Chapter 32. Immunometabolism of systemic lupus erythematosus - p. 445 36. Chapter 33. Epigenetics - p. 461 37. Chapter 34. Modeling lupus in mice - p. 481 38. Part III. Mechanisms of tissue damage - p. P3 39. Chapter 35. Pathogenesis of lupus nephitis - p. 499 40. Chapter 36. Mechanisms of vascular damage in systemic lupus erythematosus - p. 517 41. Chapter 37. Mechanisms involved in skin injury - p. 529 42. Chapter 38. Pathogenesis of tissue injury in the brain in patients with systemic lupus erythematosus - p. 541 43. Part IV. Clinical aspects of the disease - p. P4 44. Chapter 39. Constitutional symptoms and fatigue in systemic lupus erythematosus - p. 551 45. Chapter 40. The musculoskeletal system in SLE - p. 565 46. Chapter 41. Cutaneous lupus erythematosus - p. 579 47. Chapter 42. The clinical evaluation of kidney disease in systemic lupus erythematosus - p. 591 48. Chapter 43. The pathology of lupus nephritis - p. 605 49. Chapter 44. Cardiovascular disease in systemic lupus erythematosus: An update - p. 633 50. Chapter 45. The lung in systemic lupus erythematosus - p. 649 51. Chapter 46. Vasculitis in SLE - p. 663 52. Chapter 47. Gastrointestinal, hepatic, and pancreatic disorders in systemic lupus erythematosus - p. 667 53. Chapter 48. Infections in patients with systemic lupus erythematosus - p. 683 54. Chapter 49. Malignancies in systemic lupus erythematosus - p. 701 55. Chapter 50. The nervous system in systemic lupus erythematosus - p. 717 56. Chapter 51. Psychiatric lupus - p. 731 57. Chapter 52. Overlap syndromes - p. 747 58. Chapter 53. Systemic lupus erythematosus and the eye - p. 755 59. Chapter 54. Fertility and pregnancy in systemic lupus erythematosus - p. 771 60. Chapter 55. Neonatal lupus: Clinical spectrum, biomarkers, pathogenesis, and approach to treatment - p. 781 61. Chapter 56. Incomplete lupus syndromes - p. 799 62. Chapter 57. Lupus in children and adolescents - p. 807 63. Chapter 58. Drug-induced lupus - p. 817 64. Chapter 59. Accrual of organ damage in lupus - p. 831 65. Part V. Antiphospholipid syndrome - p. P5 66. Chapter 60. Pathogenesis of antiphospholipid syndrome - p. 841 67. Chapter 61. Antibodies and diagnostic tests in antiphosholipid syndrome - p. 853 68. Chapter 62. Clinical manifestations - p. 867 69. Part VI. Treatment of the disease - p. P6 70. Chapter 63. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus - p. 877 71. Chapter 64. The antimalarials in the treatment of lupus - p. 885 72. Chapter 65. Systemic glucocorticoids - p. 895 73. Chapter 66. Cytotoxic drug treatment - p. 911 74. Chapter 67. Treatment of antiphospholipid syndrome - p. 925 75. Chapter 68. New treatments for systemic lupus erythematosus - p. 933 76. Chapter 69. Cellular therapies for lupus - p. 947 77. Index - p. 959
